24/7 Patient Assistance: 760-405-8205

Mitchell Kamrava, MD

Radiation Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Hospitals & Clinics

specialties & services

  • Bio & Insurance Information

    Dr. Mitchell Kamrava is a board-certified radiation oncologist based in Los Angeles, California. He graduated from the University of California San Diego School of Medicine and then did his internship at the Stanford University. He completed his residency at the National Cancer Institute and also did a fellowship at the UCLA Medical Center. Dr. Kamrava has been practicing for about 20 years and is presently affiliated with the Cedars-Sinai Medical Center. He has also contributed to several publications.

  • Education & Training


    University of California San Diego

    Medical School


    Stanford University



    National Cancer Institute



    UCLA Medical Center


  • Board Certifications

    American Board of Radiology - Radiation Oncology

  • Hospital & Practice

    Cedars-Sinai Medical Center

    Languages: English/Spanish

    (310) 423-3277

    8700 Beverly Blvd

    Los Angeles, California 90048

    Read More
  • Publications & Memberships

    Dr. Mitchell Kamrava has contributed to 3 publications.

    High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.

    Hauswald, H.,Kamrava, M. R.,Fallon, J. M.,Wang, P. C.,Park, S. J.,Van, T.,Borja, L.,Steinberg, M. L.,Demanes, D. J.; Int. J. Radiat. Oncol. Biol. Phys.. 2015 Oct 08.

    See more >>

    Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma.

    Fallon, J.,Park, S. J.,Yang, L.,Veruttipong, D.,Zhang, M.,Van, T.,Wang, P. C.,Fekete, A. M.,Cambeiro, M.,Kamrava, M.,Steinberg, M. L.,Demanes, D. J.; Gynecol. Oncol.. 2016 Dec 29.

    See more >>

    Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer.

    Wang, C.,King, C. R.,Kamrava, M.,Iwamoto, K. S.,Chen, A. M.,Low, D.,Kupelian, P. A.,Steinberg, M. L.; Radiother Oncol. 2017 Feb 12.

    See more >>